We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Simulations Plus Releases GastroPlus™ Version 7.0
Product News

Simulations Plus Releases GastroPlus™ Version 7.0

Simulations Plus Releases GastroPlus™ Version 7.0
Product News

Simulations Plus Releases GastroPlus™ Version 7.0

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Simulations Plus Releases GastroPlus™ Version 7.0"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Simulations Plus, Inc. has announced the launch of Version 7.0 of GastroPlus, the industry’s gold standard software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics.

Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, “Version 7.0 is the largest single upgrade in the history of GastroPlus. In this version, we have added three major new capabilities that we expect to expand the use of GastroPlus throughout the pharmaceutical industry and provide new functionality that we believe will attract researchers in environmental toxicology as well.”

GastroPlus Version 7.0 now incorporates:

• Drug-drug interaction
• Ocular drug delivery
• Nasal/pulmonary drug delivery
• Numerous expansions to the basic program and modules for additional user convenience

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The one advantage that some of our competition has had over GastroPlus has been drug-drug interaction. Now, after two years of working with Roche, we have released the most advanced drug-drug interaction capability in the industry. This required a major architectural change to the program, and Dr. Lukacova and her team have done a remarkable job of developing, testing, and documenting this new capability. At the same time, we have added two new market-expanding capabilities for simulating drug delivery to the eye and via nasal/pulmonary passages.”

He continued, “We have potential customers working in these areas who have been eagerly waiting for this release. We are expecting additional sales in the very near future as a result of these capabilities. Especially noteworthy is the fact that all three of these new capabilities were developed under funded collaborations with top-five pharmaceutical companies, minimizing our capitalized expenses.”